Evidence map›Paper›PMID 41565925›Full record

ArticleNPJ precision oncology2026

An interpretable deep learning model for predicting endometrial cancer molecular subtypes from H&E-stained slides.

Qinhao Guo, Haoyu Cui, Yangyang Zhang, Shaoxian Tang, Weicheng Yan, Xiaoyan Zhou, Hongmei Ding, Jinhua Zhou, Xingzhu Ju, Zheng Feng and 8 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Qinhao Guo *Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Haoyu Cui *Jiangsu Key Laboratory of Intelligent Medical Image Computing, School of Artificial Intelligence, Nanjing University of Information Science and Technology, Nanjing, China.
Yangyang Zhang *Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Shaoxian Tang *Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Weicheng YanJiangsu Key Laboratory of Intelligent Medical Image Computing, School of Artificial Intelligence, Nanjing University of Information Science and Technology, Nanjing, China.
Xiaoyan ZhouDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Hongmei DingDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jinhua ZhouDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xingzhu JuDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Zheng FengDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Jun ZhuDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Fang BaiDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Yanping ZhongDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Haiming LiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Jun XuJiangsu Key Laboratory of Intelligent Medical Image Computing, School of Artificial Intelligence, Nanjing University of Information Science and Technology, Nanjing, China. jxu@nuist.edu.cn.
Xiaohua WuDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China. wu.xh@fudan.edu.cn.
Xiangxue WangJiangsu Key Laboratory of Intelligent Medical Image Computing, School of Artificial Intelligence, Nanjing University of Information Science and Technology, Nanjing, China. xwang@nuist.edu.cn.
Hao WenDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China. wenhao_fdc@163.com.

Funding

National Natural Science Foundation of China 82272898Science and Technology Commission of Shanghai Municipality 21ZR1415000Shanghai Shenkang Hospital Development Center SHDC2020CR5003-001
6 · The paper itself

Abstract

The molecular subtype of endometrial cancer is important for predicting prognosis and treatment effectiveness. This study aimed to develop an interpretable deep learning model based on H&E-stained whole slide images (WSIs) to predict the molecular subtype of endometrial cancer. Data from the Fudan cohort (n = 364) were used to train an end-to-end prediction network for identifying four molecular subtypes. Two external cohorts-the TCGA (n = 296) and Suzhou (n = 36)-were used to validate model generalizability and potential clinical applicability. We further assessed the correlation between histological and molecular features at both the macro- (WSI) and micro- (patch) levels. The network achieved a macro-average area under the receiver operating characteristic curve (AUROC) of 0.867 (95% CI: 0.823-0.911) in 5-fold cross-validation. The class-wise AUROCs were 0.846 (95% CI: 0.798-0.894) for the microsatellite instability-high (MSI-H) subtype, 0.876 (95% CI: 0.831-0.921) for the nonspecific molecular profile (NSMP) subtype, 0.910 (95% CI: 0.818-1.000) for the p53-abnormal (p53abn) subtype, and 0.835 (95% CI: 0.784-0.886) for the POLE-mutated (POLEmut) subtype. Morphological analysis revealed that MSI-H-subtype tumors exhibited increased stromal lymphocytic infiltration; POLEmut tumors showed higher heterogeneity, solid growth patterns, and elevated tumor grade; p53abn tumors were characterized by papillary growth and serous-like features; while NSMP tumors demonstrated high stromal cellularity. This method provides an accurate and interpretable tool for molecular subtype prediction, offering a theoretical basis for future individualized treatment strategies in endometrial cancer.

Identifiers

PMID41565925
PMCPMC12920745

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.